Abstract
Purpose: Long-term follow-up data of a randomized trial that compared hydroxyurea and the hypoxic-cell radiosensitizer to misonidazole as adjuncts to standard radiation therapy in locally advanced carcinoma of the cervix are reported. Patients and Methods: Three hundred eight women were entered, and all 294 eligible patients are assessable as randomized. Eighty-one percent of patients have been monitored for 5 years or to death. Results: There was an advantage for hydroxyurea in progression-free interval and survival (P = .05 and P = .066, respectively). There was no significant difference in the distribution of sites of failure between the regimens. For the 39% of patients with stages III to IVA disease, the advantage in progression-free interval for hydroxyurea was significant (47.8% v 33.6%). More leukopenia occurred on the hydroxyurea regimen than on the misonidazole regimen. Conclusion: In summary, these data provide stronger evidence than our previous analysis that hydroxyurea is superior to misonidazole as an adjunct to radiation therapy. For patients with locally advanced carcinoma of the cervix, hydroxyurea continues to be the adjunct of choice with radiation.
| Original language | English |
|---|---|
| Pages (from-to) | 1523-1528 |
| Number of pages | 6 |
| Journal | Journal of Clinical Oncology |
| Volume | 11 |
| Issue number | 8 |
| State | Published - 1993 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
Hydroxyurea versus misonidazole with radiation in cervical carcinoma : Long-term follow-up of a gynecologic oncology group trial. / Stehman, Frederick; Bundy, Brian N.; Thomas, Gillian; Keys, Henry M.; D'Ablaing, Gerrit; Fowler, Wesley C.; Mortel, Rodrigue; Creasman, William T.
In: Journal of Clinical Oncology, Vol. 11, No. 8, 1993, p. 1523-1528.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Hydroxyurea versus misonidazole with radiation in cervical carcinoma
T2 - Long-term follow-up of a gynecologic oncology group trial
AU - Stehman, Frederick
AU - Bundy, Brian N.
AU - Thomas, Gillian
AU - Keys, Henry M.
AU - D'Ablaing, Gerrit
AU - Fowler, Wesley C.
AU - Mortel, Rodrigue
AU - Creasman, William T.
PY - 1993
Y1 - 1993
N2 - Purpose: Long-term follow-up data of a randomized trial that compared hydroxyurea and the hypoxic-cell radiosensitizer to misonidazole as adjuncts to standard radiation therapy in locally advanced carcinoma of the cervix are reported. Patients and Methods: Three hundred eight women were entered, and all 294 eligible patients are assessable as randomized. Eighty-one percent of patients have been monitored for 5 years or to death. Results: There was an advantage for hydroxyurea in progression-free interval and survival (P = .05 and P = .066, respectively). There was no significant difference in the distribution of sites of failure between the regimens. For the 39% of patients with stages III to IVA disease, the advantage in progression-free interval for hydroxyurea was significant (47.8% v 33.6%). More leukopenia occurred on the hydroxyurea regimen than on the misonidazole regimen. Conclusion: In summary, these data provide stronger evidence than our previous analysis that hydroxyurea is superior to misonidazole as an adjunct to radiation therapy. For patients with locally advanced carcinoma of the cervix, hydroxyurea continues to be the adjunct of choice with radiation.
AB - Purpose: Long-term follow-up data of a randomized trial that compared hydroxyurea and the hypoxic-cell radiosensitizer to misonidazole as adjuncts to standard radiation therapy in locally advanced carcinoma of the cervix are reported. Patients and Methods: Three hundred eight women were entered, and all 294 eligible patients are assessable as randomized. Eighty-one percent of patients have been monitored for 5 years or to death. Results: There was an advantage for hydroxyurea in progression-free interval and survival (P = .05 and P = .066, respectively). There was no significant difference in the distribution of sites of failure between the regimens. For the 39% of patients with stages III to IVA disease, the advantage in progression-free interval for hydroxyurea was significant (47.8% v 33.6%). More leukopenia occurred on the hydroxyurea regimen than on the misonidazole regimen. Conclusion: In summary, these data provide stronger evidence than our previous analysis that hydroxyurea is superior to misonidazole as an adjunct to radiation therapy. For patients with locally advanced carcinoma of the cervix, hydroxyurea continues to be the adjunct of choice with radiation.
UR - http://www.scopus.com/inward/record.url?scp=0027165660&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027165660&partnerID=8YFLogxK
M3 - Article
VL - 11
SP - 1523
EP - 1528
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
SN - 0732-183X
IS - 8
ER -